Scholar Rock Q4 net loss widens; secures new debt facility

Scholar Rock Holding

03/03/2026 12:10

Amends Key Details table after Scholar Rock corrects FY loss per share to $3.29, from $0.88

Overview

Biopharmaceutical firm's Q4 2025 net loss widened to $91 mln, no revenue recorded

Company secured up to $550 mln in non-dilutive capital for apitegromab commercialization

Apitegromab U.S. and European launches expected in 2026, pending regulatory approvals

Outlook

Scholar Rock expects U.S. launch of apitegromab in 2026 after FDA approval

EMA decision on apitegromab MAA anticipated mid-2026, European launch in H2 2026

Company plans to submit sBLA for second fill-finish facility later in 2026

Result Drivers

FDA MEETING - Constructive meeting with FDA and Catalent Indiana, no additional corrective actions required, supports BLA resubmission plans

DEBT FACILITY - Secured up to $550 mln in non-dilutive capital to support apitegromab commercialization and pipeline advancement

PIPELINE ADVANCEMENT - Ongoing development of apitegromab for SMA with anticipated U.S. and European launches in 2026

Company press release: ID:nBw1ljMFca

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
-$3.29
FY Net Income
-$377.94 mln
FY Income from Operations
-$384.65 mln
FY Operating Expenses
$384.65 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Scholar Rock Holding Corp is $50.00, about 15% above its March 2 closing price of $43.48

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)